Enfusion (NYSE:ENFN) Price Target Raised to $13.00

Enfusion (NYSE:ENFN) had its price target raised by Stifel Nicolaus from $11.00 to $13.00 in a research note published on Wednesday morning,Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

Enfusion Stock Up 1.5 %

Shares of Enfusion stock opened at $10.63 on Wednesday. Enfusion has a 12-month low of $7.52 and a 12-month high of $11.38. The stock has a market capitalization of $1.37 billion, a P/E ratio of 265.82, a price-to-earnings-growth ratio of 3.98 and a beta of 0.97. The company has a 50-day simple moving average of $9.70 and a 200 day simple moving average of $9.00.

Insider Activity

In related news, COO Neal Pawar sold 21,801 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $10.03, for a total transaction of $218,664.03. Following the transaction, the chief operating officer now owns 1,143,544 shares in the company, valued at $11,469,746.32. This represents a 1.87 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 36.44% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Enfusion

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. RiverPark Advisors LLC bought a new stake in shares of Enfusion during the second quarter valued at approximately $68,000. Arizona State Retirement System bought a new position in Enfusion in the 2nd quarter valued at $86,000. Harbor Capital Advisors Inc. increased its stake in shares of Enfusion by 12.4% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock valued at $113,000 after buying an additional 1,315 shares during the period. Belvedere Trading LLC bought a new stake in shares of Enfusion during the third quarter worth $114,000. Finally, Paloma Partners Management Co acquired a new position in shares of Enfusion during the third quarter valued at $157,000. Institutional investors and hedge funds own 81.05% of the company’s stock.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.